This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Intuitive Surgical earnings conference call will kick off at 4:30 pm ET.
Procedure growth re-accelerated to 20 %, led by da Vinci 5 efficiency gains and Ion adoption.
System placements jumped 13 % YoY, with da Vinci 5 accounting for > 50 % of new installs.
Margins held near 67 % non-GAAP, outperforming tariff expectations.
$1.9 B share buyback shows confidence in cash-flow visibility.
Guidance tightened slightly — more clarity on tariff impact but no change to growth trajectory.
International mix solidifying with broad adoption in Asia and Europe.
The stock is now down -6% after hours. Here are the operating metrics from the quarter:
| KPI | Actual Q3 2025 | YoY Change | Why Investors Care |
|---|---|---|---|
| Total Revenue | $2.51 B | +23 % | Accelerating from +18 % Q2 trend — confirming sustainable demand. |
| Instruments & Accessories Revenue | $1.52 B | +20 % | Proxy for utilization — continued strength in procedure volume. |
| Systems Revenue | $590 M | +33 % | Driven by 427 placements (240 da Vinci 5 vs 110 last year). |
| Services Revenue | $396 M | +20 % | Installed base up 13 % to 10,763 systems. |
| Non-GAAP Op Income | $976 M | +29 % | Shows strong flow-through despite tariff hit. |
| Non-GAAP EPS | $2.40 | +30 % | High-quality beat — includes $0.12 tax benefit. |
| Share Repurchases | $1.92 B (4 M shares)** | — | Balanced capital return amid growth capex. |
The stock is now moving upwards of 13.6% after-hours.
| Metric | New Guide | Prior/Street View | Flag |
|---|---|---|---|
| Procedure growth | 17 – 17.5 % | 17 % prior | 📈 Raised |
| Non-GAAP gross margin | 67 – 67.5 % | ~69 % FY 2024 | ⚖️ Flat / Tariff drag ~70 bps |
| Op-expense growth | 11 – 13 % YoY | 10 % FY 2024 | ⚖️ Slightly Higher |
The outlook bakes in the tariff impact while maintaining expansion across installed base and procedures. Margins remain durable even under cost pressure.
| Metric | Actual | Consensus (Pre) | YoY | Result |
|---|---|---|---|---|
| Revenue | $2.51 B | $2.41 B | +23 % | ✅ Beat |
| EPS (Non-GAAP) | $2.40 | $1.99 | +30 % | ✅ Beat |
| GAAP EPS | $1.95 | n/a | +25 % | — |
| Procedures | +20 % YoY | — | Strong | ✅ Beat |
| System Placements | 427 units (240 da Vinci 5) | — | +13 % | ✅ Beat |
ISRG delivered a clean double-beat quarter — revenue +23%, EPS +30% — powered by robust da Vinci 5 adoption and 20% global procedure growth. Management reaffirmed 17–17.5% FY 2025 procedure growth and kept margin guidance stable despite tariff drag. The after-hours jump reflects confidence that da Vinci 5’s commercial rollout is exceeding plan.
“We’re pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and da Vinci platforms, including da Vinci 5. We remain focused on helping our customers achieve the Quintuple Aim.” — Dave Rosa, CEO
The message emphasizes execution and adoption velocity across both robotic platforms. With over 10,700 da Vinci systems in the field and 954 Ion systems (+30%), management is highlighting scale-driven flywheel momentum rather than one-time upside.
We expect Intuitive Surgical earnings to drop almost immediately after the closing bell. So we’re just about 5 minutes away from seeing how investors react to Q3 earnings.
As a reminder, this blog will continue updating the moment earnings hit.
| Quarter | EPS Surprise | 1-Day Move | 7-Day Move | 14-Day Move |
|---|---|---|---|---|
| Q2 2025 | +14.06% | –3.5% | +1.8% | +3.2% |
| Q1 2025 | +4.41% | +1.2% | +2.8% | +4.5% |
| Q4 2024 | +23.73% | +8.7% | +10.4% | +12.2% |
| Q3 2024 | +12.25% | +2.9% | +3.6% | +5.1% |
Live coverage has ended. The full story is below.
Intuitive Surgical (Nasdaq: ISRG | ISRG Price Prediction) reports third-quarter earnings after the close today.
The robotic-surgery pioneer heads into results on a remarkable run, four straight quarterly beats, a transformative new platform launch, and accelerating adoption across multiple regions. After last quarter’s 14% EPS surprise, Wall Street expects growth to normalize as da Vinci 5 scales globally and margin tailwinds flatten.
Consensus calls for Q3 EPS of $1.99 on revenue of $2.41 billion, reflecting 8% EPS and 18% sales growth year over year. Share have traded mostly sideways over the past year and down 11% so far in 2025.
| Period | Revenue | EPS (Normalized) | YoY Revenue Growth | YoY EPS Growth |
|---|---|---|---|---|
| Q3 2025 (est.) | $2.41 B | $1.99 | +18.3% | +8.0% |
| Q4 2025 (est.) | $2.67 B | $2.18 | +10.7% | −1.4% |
| FY 2025 (est.) | $9.78 B | $8.16 | +17.0% | +11.2% |
| FY 2026 (est.) | $11.21 B | $9.27 | +14.7% | +13.6% |
1. da Vinci 5 Adoption & Upgrade Cycle- Management highlighted early efficiency gains exceeding 20% per procedure and record trade-in activity. Over 100,000 procedures have now been completed on da Vinci 5. Investors will look for commentary on utilization trends and upgrade pacing as European and Japanese launches begin.
2. Force Feedback & AI-Driven Case Insights- Surgeon studies cited in Q2’s call linked Force Feedback metrics to shorter hospital stays and improved outcomes. Supply remains constrained through early 2026, but the technology could become a major differentiator in 2026 to 2027.
3. Margins & Tariff Impact- Non-GAAP gross margin stood at 66.5% last quarter. CFO Jamie Samath warned tariffs could trim 100 bps annually, partly offset by mix benefits and rising utilization.
4. International Growth & Capital Spending Visibility- India and Korea remain bright spots, while Japan, China, and Europe still face constrained hospital budgets. ISRG noted the U.K.’s 10-year NHS plan includes expanded robotic-surgery access.
5. SP and Ion Momentum- SP procedures rose 88% YoY in Q2, and Ion bronchoscopy volumes jumped 52% as Intuitive entered Australia and Korea. Continued system growth here would confirm ISRG’s diversification beyond multi-port platforms.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
Intuitive Surgical (NASDAQ: ISRG | ISRG Price Prediction) reports earnings this evening, and the bar is high. The robotic surgery pioneer has already logged four straight beats, and Wall Street sees another solid quarter…
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) reports Q2 earnings results at 4:40 PM ET tonight after the bell. The robotic surgery leader enters the earnings report tonight with a $142.05 billion market cap,…
Intuitive Surgical just posted its fifth consecutive earnings beat and management started buying back shares above current prices, yet the stock sits at a level that implies something far worse than a slowdown. One…
Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $482.22 after a 14.86% year-to-date…
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That flywheel is…
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) reports Q1 2026 results on April 21 after the bell. However, is stock is rising 2.7% today. Yet, with the stock down 16.92% year-to-date and trading well…
Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near the bottom…
Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift rather than…
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit…
